Therapeutic Strategies for Targeting Tumor Cells in TME

Relying on the technology platform of the tumor microenvironment center, Alfa Cytology offers a full range of solutions and services for investigating therapeutic strategies that for target tumor cells in the tumor microenvironment (TME), helping researchers successfully achieve their research goals.


Therapeutic Strategies for Targeting Tumor Cells in TME

Tumor molecular targeting therapy is to target the signature molecules of tumor cells and interfere with the link of cell carcinogenesis to achieve the purpose of tumor treatment, such as through inhibiting tumor cell proliferation, interfering with cell cycle, inducing tumor cell differentiation, inhibiting tumor cell metastasis, inducing tumor cell apoptosis and inhibiting tumor angiogenesis. Its effect is mainly on tumor cells, while it has little effect on normal cells. Tumor growth factor receptors, signal transduction molecules, cell cycle proteins, apoptosis regulators, protein hydrolases, and vascular endothelial growth factors can be used as molecular targets for tumor therapy.

Tumor cells contribute to tumor growth and metastasis to distant sites through chemokines that recruit endothelial cells, subvert immune surveillance, manipulate immune cells (immune editing) and eventually lead to immune escape. Tumor cells have become the subject of intensive research as potential targets for cancer therapy.


It is now clear that conventional treatments are not sufficient to overcome the ability of tumor cells to recruit endothelial cells, subvert immune surveillance, and manipulate immune cells. There are multiple therapeutic strategies that, despite some progress, still lack clear mechanisms as well as safety assurances. To develop therapeutic strategies with higher specificity and fewer side effects, Alfa Cytology has established an innovative tumor microenvironment center technology platform and is developing several technologies designed to help global collaborators develop therapeutic strategies targeting the tumor microenvironment (TME) and tumor cells. We provide insights into therapeutic strategies that target tumor cells based on their characteristics and roles, providing clues and rationale for individualized precision therapy.

Key strategies

  • Targeted therapies targeting growth factor receptors and cell membrane differentiation antigens on cell membranes

Most of the therapeutics being developed by Alfa Cytology are monoclonal antibodies targeting growth factor receptors on cell membranes and cell membrane differentiation antigens. Monoclonal antibodies specifically bind to growth factor receptors or antigens, and induce tumor immune responses by blocking cell proliferation signals, resulting in antibody dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) to kill tumor cells.

Depending on the target molecules, monoclonal antibodies can be divided into two categories: monoclonal antibodies acting on cell growth factor receptors and monoclonal antibodies acting on cell membrane differentiation antigens, such as EGFR / VEGFR / IGFR.

  • Monoclonal antibodies against cell membrane differentiation antigens

Cell membrane differentiation antigens are cell surface markers that appear during cell differentiation, maturation and activation, and are usually represented by clusters of differentiation antigens (CD). When monoclonal antibodies bind to leukocyte differentiation antigens, they kill tumor cells through ADCC and CDC effects. Some monoclonal antibodies to differentiation antigens, together with chemical drugs and radionuclides, constitute monoclonal antibody couples that allow the tumor cell-killing active substance to act specifically on tumor cells.

The monoclonal antibodies to differentiation antigens currently in clinical use include: rituximab, ibritumomab tiuxetan and tositumomab.

Note: The key strategies we focus on are always up to date, please contact us by email for more up-to-date and relevant information.

Alfa Cytology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact uscontact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.


Alfa Cytology is a service provider specializing in tumor microenvironment research.

About Us

Online Inquiry

Copyright © Alfa Cytology. All rights reserved. Cookie Policy | Privacy Policy